Structure de mise en forme 2 colonnes

Adipokines and Redox Signaling: Impact on Fatty Liver Disease.
Parola, Prof. Maurizio and Marra, Prof. Fabio (2011)
Antioxidants & Redox signaling 15(2):pp. 461-483.

Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
Lonardo A, Bellentani S, Ratziu V, Loria P; 
Expert Review of Gastroenterology & Hepatology 5 (2), 279-89 (Apr 2011)

Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.
Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, Caballería J, Martín-Duce A, Tran A, Wagner C, Luka Z, Lu SC, Castro A, Le Marchand-Brustel Y, Martínez-Chantar ML, Veyrie N, Clément K, Tordjman J, Gual P, Mato JM.
J Proteome Res.  3;9(9):4501-12.

Cognitive-Behavioral Treatment of Non-alcoholic Fatty Liver Disease: A Propensity Score-Adjusted Observational Study
Moscatiello, Simona ; Di Luzio, Raffaella ; Bugianesi, Elisabetta ; Suppini, Alessandro ; Hickman, Ingrid ; Di Domizio, Silvia ; Della Grave, Riccardo ; Marchesini.
Obesity, 19 (4). pp. 763-770.

Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells .
Aleffi, Dr.ssa Sara and Navari, Dr.ssa Nadia and Delogu, Dr.ssa Wanda and Galastri, Dr.ssa Sara and Novo, Dr.ssa Erica and Rombouts, Dr.ssa Krista and Pinzani, Prof. Massimo and Parola, Prof. Maurizio and Marra, Prof. Fabio (2011)
American Journal of Physiology - Gastrointestinal and Liver Physiology. 301(2):G210-G219.

Influence of lifestyle habits, nutritional status and insulin resistance in NAFLD.
Marcella Malavolti, Nino Carlo Battistini, Lucia Miglioli, Ilaria Bagni, Luca Borelli, Mariano Marino, Federica Scaglioni, Stefano Bellentani 
[Frontiers in Bioscience E4, 1015-1023, January 1, 2012]

C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
 Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TI, Jess T
J Hepatol. 2011 Sep;55(3):660-5

APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others.
Romero-Gómez M.
J Hepatol. 2011 Jun 23.

Clinical Uncertainties: How big a problem is non-alcoholic fatty liver disease?
Quentin M Anstee, Stuart McPherson, Christopher P Day.
BMJ 2011;343:bmj.d3897

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies.
Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK.
J Hepatol. 2011 Jul 12.

Glucokinase Links Kru¨ ppel-Like Factor 6 to the Regulation of Hepatic Insulin Sensitivity in Nonalcoholic Fatty Liver Disease;
Lars P. Bechmann,1,2* Amalia Gastaldelli,3,4* Diana Vetter,1 Gillian L. Patman,5 Laura Pascoe,4,6,Rebekka A. Hannivoort,1,7 Ursula E. Lee,1 Isabel Fiel,8 Ursula Mun˜ oz,1 Demetrio Ciociaro,3,4 Young-Min Lee,1,Emma Buzzigoli,3,4 Luca Miele,5,9 Kei Y. Hui,5 Elisabetta Bugianesi,10 Alastair D. Burt,6 Christopher P. Day,6,Andrea Mari,4,11 Loranne Agius,6 Mark Walker,4,6 Scott L. Friedman,1 and Helen L. Reeves;
Hepatology. 2012 Apr;55(4):1083-93. doi: 10.1002/hep.24793. Epub 2012 Mar 1.

A Lipid to Treat Non-Alcoholic Fatty Liver Disease – The Dawn of ‘Lipo-rehabilitation’?’ ;
Anstee Q.M. & Day C.P;
Journal of Hepatology Volume 56, Issue 4 , Pages 987-989, April 2012

Genetic Modifiers of Non-Alcoholic Fatty Liver Disease Progression' ;
Anstee Q.M., Daly A.K. & Day C.P. ;
Biochimica et Biophysica Acta - Molecular Basis of Disease, 2011, 1812(11): p.1557-66.

Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity;
Anna Ludovica Fracanzani,Luca Valenti , Elisabetta Bugianesi,Ester Vanni ,Antonio Grieco,  Luca Miele,Dario Consonni,Erika Fatta,Rosa Lombardi, Giulio Marchesini, Silvia Fargion;
Journal of Hepatology Volume 54, Issue 6 , Pages 1244-1249, June 2011

Treatment of non-alcoholic fatty liver disease with focus on emerging drugs;
Giulio Marchesini, Simona Moscatiello, Federica Agostini, Nicola Villanova, and Davide Festi;
Expert Opinion on Emerging Drugs | March 2011, Vol. 16, No. 1 : Pages 121-136

Nuclear receptors in liver disease;
Martin Wagner1,2, Gernot Zollner1,Michael Trauner3,‡,*,;
Hepatology  Volume 53, Issue 3, pages 1023–1034, March 2011

Nuclear Receptors as New Perspective for the Management of Liver Diseases , ;
Trauner Michael; Halilbasic Emina, ;
GASTROENTEROLOGY 2011: 140 , 4; 1120. Published: APR 2011

Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease.; Chavez-Tapia NC, Rosso N, Tiribelli C.; BMC Gastroenterol. 2012 Mar 1;12:20.Lack of chemokine (C-C motif) ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis;
Sara Galastri, Elena Zamara, Stefano Milani, Erica Novo, Angela Provenzano, Wanda Delogu, Francesco Vizzutti, Salvatore Sutti, Irene Locatelli, Nadia Navari, Elisa Vivoli, Alessandra Caligiuri, Massimo Pinzani, Emanuele Albano, Maurizio Parola, Fabio Marra;
Clinical Science 04/2012; 123(7):459-71.

Vitamin D and the vitamin D receptor in liver pathophysiology;
Silvia Zúñiga, Delphine Firrincieli, Chantal Housset, Nicolas Chignard;
Clinics and Research in Hepatology and Gastroenterology, Volume 35, Issue 4, Pages 295-302

Fibrogenesis in nonalcoholic steatohepatitis;
Samuele De Minicis and Gianluca Svegliati-Baroni;
Expert Review of Gastroenterology & Hepatology | April 2011, Vol. 5, No. 2, Pages 179-187

Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome;
Simona Moscatiello, Raffaella Di Luzio, Anna Simona Sasdelli & Giulio Marchesini ;
Expert Opinion on Pharmacotherapy December 2011, Vol. 12, No. 17 , Pages 2657-2672

Bariatric surgery, adipose tissue and gut microbiota;
K Clément;

International Journal of Obesity 35, S7-S15 (September 2011)

Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease , ;
Thierry Claudel, Gernot Zollner, Martin Wagner, Michael Trauner;

Nuclear Receptors in Liver Disease ; 
Wagner Martin; Zollner Gernot; Trauner Michael, ;
HEPATOLOGY 2011:53: 3: 1023-1034

Absence of adipose triglyceride lipase protects from hepatic ER stress;
Claudia D. Fuchs1,2, Thierry Claudel1,2, Pooja Kumari1,2, Guenter Haemmerle3, Marion J. Pollheimer1, Tatjana Stojakovic4, Hubert Scharnagl4, Emina Halilbasic1,2, Judith Gumhold1, Dagmar Silbert1, Harald Koefeler5, Michael Trauner1,2,§,*;
Hepatology |  Volume 56, Issue 1, pages 270–280, July 2012

Reliability Of A Multisensor Armband In Estimating Energy Expenditure According To Degree Of Obesity ;
Stefano Bellentani, M.D., Ph.D.; Nino Carlo Battistini, M.D., Stefania Ciccia, M.D., Federica Scaglioni, M.D., Alessia Procaccini P.D., Mariano Marino, N.D., Paola Loria, M.D., Erica Villa, M.D.; J Obes Weig los Ther 2:116

Waist Circumference Adjusted for Body Mass Index and Intra-Abdominal Fat Mass. ;
Berentzen TL, Ängquist L, Kotronen A, Borra R, Yki-Järvinen H, et al. ;
PLoS ONE 7(2) 2012

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.;
Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, Clement K.;
Hepatology. 2012 Jun 18.

Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis.;
Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M'kada H, Ratziu V, Hannoun L, Charlotte F.;
Clin Gastroenterol Hepatol. 2012 Feb 14.